Progen Co., Ltd.
🇰🇷South Korea
Clinical Trials
2
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
Phase 2
Active, not recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Obesity Type 2 Diabetes Mellitus
- Interventions
- Other: Placebo
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- ProGen. Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06712615
- Locations
- 🇰🇷
The Catholic University of KOREA, Bucheon St.Mary's Hostital, Bucheon, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Daejeon Eul Ji Medical Center, Eul Ji University, Daejeon, Korea, Republic of
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- ProGen. Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT06309667
- Locations
- 🇰🇷
Catholic University Seoul St.Mary Hospital,, Seocho, Seoul, Korea, Republic of
News
No news found